{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:02:42Z","timestamp":1767988962034,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.vaccine.2010.06.085","type":"journal-article","created":{"date-parts":[[2010,7,8]],"date-time":"2010-07-08T08:28:09Z","timestamp":1278577689000},"page":"6028-6035","source":"Crossref","is-referenced-by-count":13,"title":["Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model"],"prefix":"10.1016","volume":"28","author":[{"given":"Melanie R.","family":"Bui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Leopold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaodong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Fiolkoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Duke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Apelian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Franzusoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"DeGregori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.06.085_bib1","first-page":"1488","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"issue":"June (5405)","key":"10.1016\/j.vaccine.2010.06.085_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"October (15)","key":"10.1016\/j.vaccine.2010.06.085_bib3","first-page":"990","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N Engl J Med"},{"issue":"May (8749)","key":"10.1016\/j.vaccine.2010.06.085_bib4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0140-6736(91)91706-Z","article-title":"Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction","volume":"337","author":"Maurer","year":"1991","journal-title":"Lancet"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2010.06.085_bib5","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V80.12.2983.2983","article-title":"Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762)","volume":"80","author":"Westbrook","year":"1992","journal-title":"Blood"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2010.06.085_bib6","first-page":"1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"issue":"April (17)","key":"10.1016\/j.vaccine.2010.06.085_bib7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"April (14)","key":"10.1016\/j.vaccine.2010.06.085_bib8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"March (11)","key":"10.1016\/j.vaccine.2010.06.085_bib9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2010.06.085_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11912-009-0046-y","article-title":"Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?","volume":"11","author":"Quintas-Cardama","year":"2009","journal-title":"Curr Oncol Rep"},{"issue":"9 (Sep)","key":"10.1016\/j.vaccine.2010.06.085_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","article-title":"Imatinib and beyond\u2014exploring the full potential of targeted therapy for CML","volume":"6","author":"Quintas-Cardama","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"October (47)","key":"10.1016\/j.vaccine.2010.06.085_bib12","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","article-title":"Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias","volume":"22","author":"Shah","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.vaccine.2010.06.085_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1101\/sqb.2008.73.039","article-title":"The INK4-ARF (CDKN2A\/B) locus in hematopoiesis and BCR-ABL-induced leukemias","volume":"73","author":"Williams","year":"2008","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2010.06.085_bib14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"issue":"December (24)","key":"10.1016\/j.vaccine.2010.06.085_bib15","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2010.06.085_bib16","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"issue":"June (24)","key":"10.1016\/j.vaccine.2010.06.085_bib17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"June (24)","key":"10.1016\/j.vaccine.2010.06.085_bib18","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"June (24)","key":"10.1016\/j.vaccine.2010.06.085_bib19","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1073\/pnas.0600001103","article-title":"Activity of dual SRC-ABL inhibitors highlights the role of BCR\/ABL kinase dynamics in drug resistance","volume":"103","author":"Azam","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"October (7)","key":"10.1016\/j.vaccine.2010.06.085_bib20","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2007-06-094508","article-title":"Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation","volume":"110","author":"de Lavallade","year":"2007","journal-title":"Blood"},{"issue":"July (14)","key":"10.1016\/j.vaccine.2010.06.085_bib21","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia","volume":"14","author":"Quintas-Cardama","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2010.06.085_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2010.06.085_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"April (2 Suppl. 2)","key":"10.1016\/j.vaccine.2010.06.085_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/shem.2003.50046","article-title":"Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment","volume":"40","author":"Roche-Lestienne","year":"2003","journal-title":"Semin Hematol"},{"issue":"August (15)","key":"10.1016\/j.vaccine.2010.06.085_bib25","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1158\/0008-5472.CAN-04-1487","article-title":"Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy","volume":"64","author":"Lu","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2010.06.085_bib26","series-title":"Coupling Innate Adaptive Immunity with Yeast-Based Cancer Immunotherapy","author":"Munson","year":"2008"},{"issue":"June (5)","key":"10.1016\/j.vaccine.2010.06.085_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00251-005-0798-y","article-title":"Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications","volume":"57","author":"Bui","year":"2005","journal-title":"Immunogenetics"},{"issue":"August (10)","key":"10.1016\/j.vaccine.2010.06.085_bib28","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s002510000217","article-title":"An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries","volume":"51","author":"Udaka","year":"2000","journal-title":"Immunogenetics"},{"issue":"September (14)","key":"10.1016\/j.vaccine.2010.06.085_bib29","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/bioinformatics\/btg247","article-title":"Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules","volume":"19","author":"Peters","year":"2003","journal-title":"Bioinformatics"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2010.06.085_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.152.1.163","article-title":"Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains","volume":"152","author":"Parker","year":"1994","journal-title":"J Immunol"},{"issue":"November (3\u20134)","key":"10.1016\/j.vaccine.2010.06.085_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002510050595","article-title":"SYFPEITHI: database for MHC ligands and peptide motifs","volume":"50","author":"Rammensee","year":"1999","journal-title":"Immunogenetics"},{"key":"10.1016\/j.vaccine.2010.06.085_bib32","unstructured":"Vladimir Brusic GR, Leonard C. Harrison Prediction of MHC Binding Peptides Using Artificial Neural Networks. Complexity International 1995, 1995; 02"},{"issue":"August (5072)","key":"10.1016\/j.vaccine.2010.06.085_bib33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1126\/science.1323877","article-title":"Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb","volume":"257","author":"Fremont","year":"1992","journal-title":"Science"},{"issue":"March (7)","key":"10.1016\/j.vaccine.2010.06.085_bib34","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1073\/pnas.92.7.2479","article-title":"Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove","volume":"92","author":"Fremont","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"May (2)","key":"10.1016\/j.vaccine.2010.06.085_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/bib\/2.2.195","article-title":"Swiss-PDB viewer (deep view)","volume":"2","author":"Kaplan","year":"2001","journal-title":"Brief Bioinform"},{"issue":"September (Pt 5)","key":"10.1016\/j.vaccine.2010.06.085_bib36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1107\/S0907444998003254","article-title":"Crystallography & NMR system: a new software suite for macromolecular structure determination","volume":"54","author":"Brunger","year":"1998","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"42","key":"10.1016\/j.vaccine.2010.06.085_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1107\/S0108767390010224","article-title":"mproved methods for building protein models in electron density maps and the location of errors in these models","volume":"2","author":"Jones","year":"1991","journal-title":"Acta Crystallogr Sect A"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2010.06.085_bib38","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1371\/journal.pbio.0030401","article-title":"Impaired DNA replication within progenitor cell pools promotes leukemogenesis","volume":"3","author":"Bilousova","year":"2005","journal-title":"PLoS Biol"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2010.06.085_bib39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/87974","article-title":"Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity","volume":"7","author":"Stubbs","year":"2001","journal-title":"Nat Med"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2010.06.085_bib40","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"December (56)","key":"10.1016\/j.vaccine.2010.06.085_bib41","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1038\/sj.onc.1206091","article-title":"Studying the pathogenesis of BCR-ABL+ leukemia in mice","volume":"21","author":"Van Etten","year":"2002","journal-title":"Oncogene"},{"issue":"April (17)","key":"10.1016\/j.vaccine.2010.06.085_bib42","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1073\/pnas.0602030103","article-title":"Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia","volume":"103","author":"Williams","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2010.06.085_bib43","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10009266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10009266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:11:37Z","timestamp":1685664697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10009266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":43,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0264410X10009266"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.085","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}